SESAUA 2024: Time Interval Between Radium-223 Therapy and 177Lu-PSMA Treatment for mCRPC and Outcomes in the RALU Study SESAUA 2024: State of the Art Lecture: Management of Complications Following ...
Robotic/laparoscopic prolapse repair and the role of hysteropexy: A urology perspective, "Beyond the Abstract," by Daniel S. Elliott, MD ...
(UroToday.com) The 2024 GU ASCO annual meeting featured a session on the role of immunotherapy in advanced urothelial carcinoma and a presentation by Dr. Peter O'Donnell discussing drug sequencing, ...
ASTRO 2021: 10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation Therapy in Localized Prostate Cancer ASTRO 2021: Impact of AR-V7 and Other ...
IBCN 2024: Quantifying Intra-tumoral Molecular Subtype Heterogeneity in MIBC from Histological Slides using a deep learning approach in the VESPER Trial IBCN 2024: Oncolytic Virotherapy Expressing a ...
WCET 2025: State of the Art Lecture: Kidney in a Bag: The Next Frontier for Urologic Innovation and Discovery? WCET 2025: State of the Art Lecture: The Role of 3D Printing in Surgery WCET 2025: State ...
BOND-003 Trial: Cretostimogene Grenadenorepvec Shows Promise in BCG-Unresponsive NMIBC - Mark Tyson Breaking Paradigms: BOND-003's Cretostimogene Monotherapy for High-Risk, BCG-Unresponsive Non-Muscle ...
ASCO GU 2018: Phase II Trial of 6 Months ADT/Abiraterone Acetate Plus Prednisone and Definitive Radiotherapy - Intermediate to High Risk Localized Prostate Cancer - AbiRT Trial ASCO GU 2018: ...
APCCC Diagnostics 2025: What Do You Want to Have Reported in MRI and PSMA PET?
ESMO 2024: Identification of Bladder Cancer Patients That Could Benefit from Early Post-Cystectomy Immunotherapy Based on Serial Circulating Tumour DNA Testing: Preliminary Results from the TOMBOLA ...
Phase 3 Trial Results for Intravesical Cretostimogene Grenadenorepvec in Bladder Cancer - Mark Tyson CORE-008 Trial Cohort CX: Combining Cretostimogene Grenadenorepvec and Gemcitabine for Bladder ...
Combination Treatment or ADT Alone: Advancing Knowledge on Informed Treatment decisions in Advanced Prostate Cancer Sent on 22 December 2025 Receive via e-mail ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results